Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
06/2005
06/01/2005EP1114030B1 Pyridine ketones useful as herbicides
06/01/2005EP0991625B1 Inhibitors of factor xa with a neutral p1 specificity group
06/01/2005EP0708756B1 Substituted 2-phenylpyridines with herbicidal action
06/01/2005CN1622942A HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
06/01/2005CN1204128C Process for preparation of oxazole derivatives
05/2005
05/31/2005US6900345 Antibiotics; mutilin 14-[N-(2-carbamoyloxyethoxycarbonyl)]carbamate; therapy for bacteria infections; chemical synthesis
05/31/2005US6900342 Chemical intermediates; anticancer agents
05/31/2005US6900329 MCH antagonists and their use in the treatment of obesity
05/31/2005US6900232 For therapy of tumor metastasis, solid tumor growth (neoplasia), osteoporosis, Paget's disease, humoral hypercalcemia of malignancy, osteopenia, angiogenesis, including tumor angiogenesis and lymphangiogenesis
05/31/2005US6900214 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
05/31/2005US6900207 N-containing five-membered ring compounds and pharmaceutical agents comprising the same as active ingredient
05/31/2005US6900202 Nicotinic acetylcholine receptor activators; treating neurodegenerative disorders
05/31/2005US6899739 Hair dyes
05/26/2005WO2005047524A2 Compositions and methods for inducing cell dedifferentiation
05/26/2005WO2005047272A1 Morpholine derivatives as norepinephrine reuptake inhibitors
05/26/2005WO2005047247A1 Novel1,3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands
05/26/2005WO2005047246A1 Novel 1, 3-disubstituted azetidine deivatives for use as 5ht2a receptor ligands
05/26/2005WO2005047244A2 Inhibition of fgfr3 and treatment of multiple myeloma
05/26/2005WO2005046698A1 Fused heterocyclic compounds
05/26/2005WO2005046688A2 Methods of use of thrombin receptor antagonists
05/26/2005WO2005046682A1 Therapeutic compounds and uses thereof
05/26/2005WO2005046679A1 Immuno inhibitory pyrazolone compounds
05/26/2005WO2005046604A2 Heteroaryl-hydrazone compounds
05/26/2005WO2005046603A2 Pyridine compounds
05/26/2005WO2005046590A2 Methods for synthesizing quinolinone compounds
05/26/2005WO2005046589A2 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005WO2005019168A8 Fluorinated lysine derivatives as dipeptidyl peptidase iv inhibitors
05/26/2005WO2004112719A8 Chemical compounds
05/26/2005WO2004111000A3 Piperidyl derivatives and their use as tachykinin antagonists
05/26/2005WO2004108686A3 Benzimidazole compounds having hypoglycemic activity
05/26/2005WO2004108664A3 Bicyclic heterocycles, drugs containing said compounds, the use thereof and method for preparing the same
05/26/2005US20050113579 Antitumor agents; formed by refluxing mixture of amonafide with acetic acid
05/26/2005US20050113575 Nile red luminescent comp0und emitting red light, process for producing the same, and luminescent element utilizing the same
05/26/2005US20050113574 Contains 1-(2-Aminoethyl)piperidine and 2-adamantanone; mycobacterial infections
05/26/2005US20050113451 7-acetamidinyl derivatives
05/26/2005US20050113450 method of sterilization, sanitation, antisepsis, and disinfection, includes applying antimicrobial compounds to a surface; e.g. 2-[(3-{[4-chloro(methyl)anilino]sulfonyl}benzoyl)amino]-5-(trifluoromethyl)benzoic acid
05/26/2005US20050113440 Compounds that modulate PPAR activity and methods for their preparation
05/26/2005US20050113429 E.g., 4-(2-methyl-3-oxo-hept-6-en-2-yl)-2,2-dimethyl-[1,3]-dioxane chemical intermediate; chemical/metabolic stabilization of microtubuli; antitumor, -carcinogenic agents; malignant melanoma, acute lymphocytic/myelocytic leukemia; angiogenesis inhibitors; antiinflammatory/-arthritic agents; psoriasis
05/26/2005US20050113428 2-{3,5-bis[(3-chlorobenzyl)oxy]benzyl}-1,2,4-oxadiazolidine-3,5-dione to treat disorders associated with elevated PAI-1(Plasminogen activator inhibitor) levels
05/26/2005US20050113424 E.g., 4-{3-[4-(3-{4-[amino(imino)methyl]phenoxy}propyl)-1-piperazinyl]propoxy}benzamidine; an antifungal agent with good pharmacokinetics and excellent antifungal action; side effect reduction such as nephrotoxicity; action to Mycomycetes
05/26/2005US20050113423 Modulators of ATP-binding cassette transporters
05/26/2005US20050113419 Therapeutic compounds for treating dyslipidemic conditions
05/26/2005US20050113412 Quinoline compounds and their uses
05/26/2005US20050113396 Na+/H++exchanger-3 (NHE-3) inhibitors; antiischemic agents
05/26/2005US20050113383 For therapy of allergy, allergy-induced airway responses, congestion, hypotension, cardiovascular disease, hypotension, diseases of the GI tract, hyper and hypo motility and acidic secretion of the gastrointestinal tract, obesity, sleep
05/26/2005US20050113378 As inhibitors of the retinoic acid-metabolism, as drugs; breast cancer; psoriasis
05/26/2005US20050113373 medicine to inhibit proliferative conditions, such as cancer and psoriasis; detecting or identifying a histone deactylase (HDAC) in a biological sample
05/26/2005US20050113357 Cholinergic agents such as 3-[3-(4-methoxypiperidine)-1-yl-propyl]-1H-indole; for therapy of cognitive dysfunction, forgetfulness, confusion, memory loss, attention deficits, deficits in visual perception, depression, pain, sleep disorders, and psychosis
05/26/2005US20050113356 Inhibitors of cathepsin S
05/26/2005US20050113347 Novel antibacterial compounds: process for their preparation and pharmaceutical compositions containing them
05/26/2005US20050113344 Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases
05/26/2005US20050113341 Stent with a disposed traiazine compound such as 6-(3-Chloro-4-methoxy-phenoxy)-N-cycloheptyl-N'-methyl-N'-(1-methyl-piperidin-4-yl)-[1,3,5]triazine-2,4-diamine for inhibiting smooth muscle proliferation; restenosis and atherosclerosis
05/26/2005US20050112487 electroconductive supports having layers containing azo compounds, charge transporting substance, acceptors and phenolic compounds, used in laser printer as well as high speed copiers
05/26/2005US20050112407 Organic electroluminescent device
05/26/2005US20050112197 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics
05/26/2005CA2545373A1 Novel 1,3-disubstituted azetidine derivatives for use as 5ht2a receptor ligands
05/26/2005CA2545340A1 Fused heterocyclic compounds
05/26/2005CA2545259A1 Heteroaryl-hydrazone compounds
05/26/2005CA2545258A1 Pyridine compounds
05/26/2005CA2545060A1 Methods of use of thrombin receptor antagonists
05/26/2005CA2544602A1 Therapeutic compounds and uses thereof
05/26/2005CA2544492A1 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties
05/26/2005CA2544186A1 Inhibition of fgfr3 and treatment of multiple myeloma with benzimidazole quinolinones
05/25/2005EP1533311A1 Sulfonamides and derivatives thereof that modulate the activity of endothelin
05/25/2005EP1533305A1 A process for the preparation of valsartan and intermediates thereof
05/25/2005EP1533303A1 Substituted Aminosalicylacid Amides ( intermediates )
05/25/2005EP1532142A2 Polypeptide cleavage process
05/25/2005EP1532141A1 2-pyrrolidin-2-yl- 1,3,4]-oxadiazole derivatives and the use of the same as antidepressants
05/25/2005EP1532128A1 Inhibitors of hcv ns5b polymerase
05/25/2005EP1532121A1 New use of pyrimidine - or triazine- 2-carbonitiles for treating diseases associated with cysteine protease activity and novel pyrimidine-2-carbonitile derivatives
05/25/2005EP1532103A2 Use of compounds having an amine nucleus in manufacture of a medicament useful for treating factor viia-associated conditions
05/25/2005EP1531824A2 Cyclothiocarbamative derivatives as pr modulators and use thereof for treatment of skin disorders
05/25/2005EP1531820A1 Anabaseine derivatives useful in the treatment of neurodegenerative diseases
05/25/2005EP1531819A1 USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN
05/25/2005EP1531817A1 Glycinamide derivatives as raf-kinase inhibitors
05/25/2005EP1531816A1 Spirocyclic piperidines as mch1 antagonists and uses thereof
05/25/2005EP1531812A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis
05/25/2005EP1531811A2 Derivatives of 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazole as antagonists of the gonadotropin releasing hormone (gnrh) for use in the treatment of sex hormone related conditions, such as prostatic of uterine cancer
05/25/2005EP1531810A2 Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
05/25/2005EP1286673B1 Ligands of integrin receptors
05/25/2005EP1140814B1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds
05/25/2005CN1620452A 3, 4-dihydro-1h-isoquinoloin-2-yl-derivatives
05/25/2005CN1620447A Isochroman compounds for treatment of cns disorders
05/25/2005CN1620441A Nile red type compound emitting red light, process for producing the same, and luminescent element utilizing the same
05/25/2005CN1620440A Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
05/25/2005CN1620434A Pyrrolidine-2-ones as factor Xa inhibitors
05/25/2005CN1620433A Pyrrolidine derivatives as inhibitors of endothelin-converting enzyme
05/25/2005CN1620424A Compounds for the treatment of inflammatory disorders
05/25/2005CN1620294A Pyrimidine A2b selective antagonist compounds, their synthesis and use
05/25/2005CN1203070C Thrombin receptor antagonists
05/25/2005CN1203060C Pyridine derivatives, its composition and use
05/25/2005CN1202823C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (NIDDM) attack
05/25/2005CN1202821C Use of thiazolidinedione for preventing or retaining non-insulin-dependent diabets mellitus (MIDDM) attack
05/24/2005US6897234 Asthma therapy; antiallergens; antiinflammatory agents
05/24/2005US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole
05/24/2005US6897230 Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof
05/24/2005US6897226 NK-1 receptor active amine oxide prodrugs
05/24/2005US6897214 Quinazoline derivatives
05/24/2005US6897210 Anticancer agents; antiarthritic agents
05/24/2005US6897208 Protein kinase inhibitors
1 ... 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 ... 647